A novel series of five 7-piperazin-substituted [1,3]oxazolo[4,5-d]pyrimidines have been synthesized and characterized by Infrared (IR), Proton Nuclear Magnetic Resonance (1H-NMR), Carbon-13 Nuclear Magnetic Resonance (13C-NMR) spectroscopy, elemental analysis and chromato-mass-spectrometry. The anticancer activities of the all the newly synthesized compounds were valuated via single high dose (10-5M) against 60 cancer cell lines by the National Cancer Institute according to its own screening protocol. In the next phase, the compounds have been selected for five-dose assay. Among these compounds 5-phenyl-7-piperazin-1-yl-2-p-tolyl[1,3]oxazolo[4,5-d]pyrimidine displayed the most growth inhibitory (GI50 was in range of 0.2−2.0 μM), cytostatic (TGI − 0.3-4.2 μM) and cytotoxic (LC50 − 0.6-7.8 μM with the exception of Leukemia CCRF-CEM cell line, LC50>100 μM) activities against all cancer cell lines. The most selectivity 5-phenyl-7-piperazin-1-yl-2-p-tolyl[1,3]oxazolo[4,5-d]pyrimidine demonstrated against Leukemia and Colon Cancer subpanels. These results provided evidence that compound could be useful for developing new anticancer drugs.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report